Idorsia Pharmaceuticals Ltd (IDRSF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon or good morning everyone and welcome to our half year 2026 investor webcast. My name is Kevin Boss and I'm responsible for investor relations at IDORSIA. Today, rather than simply reviewing what happened during the first six months of the year, we want to focus on what will drive the next phase of growth and value creation at IDORSIA. Joining me on the call, we have Jean-Paul Clozel, chairman and interim CEO, Benjamin Limal, head of Europe and international markets, Charlie Jacobovitz, President of Eidosia US, Martine Clozel, Chief Scientific Officer and Head of Research, Dominique Le Terrier, Global Commercial Strategy and New Product Planning, Amer Joseph, Chief Medical Officer and Head of Global Clinical Development, and Arno Groenewoud, our Chief Financial Officer. Each of them will take you through the progress being made across the business before joining the Q&A session. Next slide. As always, today's presentation contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. With that, let me hand over to Jean-Paul. Next slide. Hello, everyone. It's a pleasure to be with you today. Next slide. Let's start with a quick overview of top-line achievements. QVVX sales reached 91 million Swiss francs, an increase of 62% year-on-year, and we remain well on track to reach our full-year guidance. This performance reflects strong commercial momentum in Europe and Canada. In the United States, after resetting the business on a more efficient cost base, We are now seeing a return to growth. Benjamin and Charles will provide you more details in a few moments. I'm also delighted that Roland Vandeleur will join IDO...